Ensysce Biosciences Inc (ENSC)vsJohnson & Johnson (JNJ)
ENSC
Ensysce Biosciences Inc
$0.27
-2.56%
HEALTHCARE · Cap: $4.56M
JNJ
Johnson & Johnson
$256.98
-0.82%
HEALTHCARE · Cap: $623.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2046715% more annual revenue ($96.36B vs $4.71M). JNJ leads profitability with a 21.8% profit margin vs -250.4%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ENSC
Avoid31
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.5%
Fair Value
$1.01
Current Price
$0.27
$0.74 discount
Margin of Safety
-88.3%
Fair Value
$136.51
Current Price
$256.98
$120.47 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1149.0% — below average capital efficiency
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ENSC
The strongest argument for ENSC centers on Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : ENSC
The primary concerns for ENSC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ENSC profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
ENSC carries more volatility with a beta of 0.82 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 31/100), backed by strong 21.8% margins. ENSC offers better value entry with a 59.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ensysce Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?